Myocardial infarction hypertension and

Drug treatment of angina, myocardial infarction and hypertension... 

Propranolol is used in the treatment of arrhythmias of atrial and ventricular origin, angina pectoris, myocardial infarction, and hypertension. It is a nonselective p-blocker with action on cardiac receptors (p,) and on vascular and bronchial smooth muscle receptors ( 2) Propranolol s principal effect is to reduce the heart rate, thus relieving angina, and to slow conduction at the atrioventricular node, reducing tlie ventricular rate in patients with atrial fibrillation. It is included here as representative of other P-blockers, such as acebutalol, prindolol, esmolol, flestolol, metoprolol, nadolol, and sotalol, which are like propranolol. 

The root of Salvia miltiorrhiza has been used as Chinese folk medicine for the treatment of cardiovascular diseases, such as ischemia, angina pectoris, coronary heart disease, myocardial infarction, and hypertension. Many studies on the secondary metabolites from Salvia miltiorrhiza revealed that tanshinones were a group of compounds responsible for these biological activities, especially for the treatment of coronary artery disease and h5 rtension. 

The surgical treatment of lower-extremity ischemia must be based on the severity of the patient s symptoms and the overall medical condition of the individual. Atherosclerosis is a systemic process, and these patients are predisposed to stroke, myocardial infarction, and hypertension caused by the involvement of other arterial segments. The extent of such involvement requires full evaluation prior to lower extremity surgery, and some patients may require carotid endarterectomy or coronary artery bypass grafting or stenting before infrainguinal reconstruction is undertaken. 

There can be a number of underlying causes of CHE. The most prevalent is the lack of oxygenated blood reaching the heart muscle itself because of coronary artery disease with myocardial infarction (111). Hypertension and valvular disease can contribute to CHE as well, but to a lesser extent in terms of principal causes for the disease. 

It is well accepted that hypertension is a multifactorial disease. Only about 10% of the hypertensive patients have secondary hypertension for which causes, ie, partial coarctation of the renal artery, pheochromacytoma, aldosteronism, hormonal imbalances, etc, are known. The hallmark of hypertension is an abnormally elevated total peripheral resistance. In most patients hypertension produces no serious symptoms particularly in the early phase of the disease. This is why hypertension is called a silent killer. However, prolonged suffering of high arterial blood pressure leads to end organ damage, causing stroke, myocardial infarction, and heart failure, etc. Adequate treatment of hypertension has been proven to decrease the incidence of cardiovascular morbidity and mortaUty and therefore prolong life (176—183). 

Adverse reactions include transitory stinging on initial instillation, blurring of vision, mydriasis, increased redness, irritation, discomfort, and increased IOP. Systemic adverse reactions include headache, browache, palpitations, tachycardia, arrhythmias, hypertension, myocardial infarction, and stroke. 

Vasopressin, alone or in combination with nitroglycerin, can no longer be recommended as first-line therapy for the management of variceal hemorrhage. Vasopressin causes nonselective vasoconstriction and can result in hypertension, severe headaches, coronary ischemia, myocardial infarction, and arrhythmias. 

Introduction of )3-adrenoblockers into medicine was one of the main advancements of pharmacology of the cardiovascular system. Initially these drags were used only in treating essential hypertension. Currently, they are used in treating angina, arrhythmia, migraines, myocardial infarctions, and glaucoma. 

It is used for stable and unstable stenocardia (including after myocardial infarctions), and for arterial hypertension. 

Atrial fibrillation is commonly associated with heart failure, and the prevalence of atrial fibrillation is related to the severity of heart failure, with less than 5% affected with very mild heart failure to nearly 50% affected with advanced heart failure [66]. Heart failure and atrial fibrillation are both common cardiovascular disorders and share the same demographic risk factors, including age, history of hypertension, prior myocardial infarction, and valvular heart disease [67, 68]. Further, the incidence of heart failure increases dramatically after the diagnosis of atrial fibrillation [69]. Progression of LV dysfunction can clearly be associated with rapid ventricular rates [70-76]. Conversely, conversion to normal sinus rhythm or control of ventricular response in atrial fibrillation can improve LV function [71-74, 77]. Accordingly, rate control becomes very important in patients with heart failure and dilated cardiomyopathy, and likely even more so when ischemia from rapid rates complicate the patient s course. 

Prevention of heart failure through identification and management of risk factors in the preclinical phase of the disease is a priority. The concept of primary prevention has significant impact on the development of heart failure. It is estimated that the risk factors of hypertension, myocardial infarction, and diabetes contribute to 80% of the heart failure diagnosed in the United States [21]. More... 

Captopril, as well as other ACE inhibitors, is indicated in the treatment of hypertension, congestive heart failure, left ventricular dysfunction after a myocardial infarction, and diabetic nephropathy. In the treatment of essential hypertension, captopril is considered first-choice therapy, either alone or in combination with a thiazide diuretic. Decreases in blood pressure are primarily attributed to decreased total peripheral resistance or afterload. An advantage of combining captopril therapy with a conventional thiazide diuretic is that the thiazide-induced hypokalemia is minimized in the presence of ACE inhibition, since there is a marked decrease in angiotensin Il-induced aldosterone release. 

Contraindications Uncontrolled adrenal cortical insufficiency, untreatedthyrotoxico-sis, treatment of obesity, uncontrolled angina, uncontrolled hypertension, uncontrolled myocardial infarction, and hypersensitivity to any component of the formulations... 

It is an anionic detergent which softens the stool by water accumulation in intestinal lumen and emulsifies the colon contents. It is indicated in obstetric, habitual, geriatric, paediatric constipation or when straining is to be avoided (recent myocardial infarction, severe hypertension, post-operative cases, abdominal hernia), fissures, haemorrhoids and bed ridden patients. Dose 100-200 mg/day. 

Finally, the toxicity of some effective drugs prevents their use at maximally effective dosage. The widespread indiscriminate use of 3 blockers has been criticized because several large clinical trials indicate that some members of the group, eg, metoprolol and carvedilol, have a greater benefit than others, eg, atenolol. However, all 3 blockers appear to have similar benefits in reducing mortality after myocardial infarction, so these drugs are particularly indicated in patients with an infarct and hypertension. 

Propranolol was the first blocker shown to be effective in hypertension and ischemic heart disease. Propranolol has now been largely replaced by cardioselective blockers such as metoprolol and atenolol. All B-adrenoceptor-blocking agents are useful for lowering blood pressure in mild to moderate hypertension. In severe hypertension, blockers are especially useful in preventing the reflex tachycardia that often results from treatment with direct vasodilators. Beta blockers have been shown to reduce mortality after a myocardial infarction and some also reduce mortality in patients with heart failure they are particularly advantageous for treating hypertension in patients with these conditions (see Chapter 13). 

ACE inhibitors have a particularly useful role in treating patients with chronic kidney disease because they diminish proteinuria and stabilize renal function (even in the absence of lowering of blood pressure). This effect is particularly valuable in diabetes, and these drugs are now recommended in diabetes even in the absence of hypertension. These benefits probably result from improved intrarenal hemodynamics, with decreased glomerular efferent arteriolar resistance and a resulting reduction of intraglomerular capillary pressure. ACE inhibitors have also proved to be extremely useful in the treatment of heart failure, and after myocardial infarction, and there is recent evidence that ACE inhibitors reduce the incidence of diabetes in patients with high cardiovascular risk (see Chapter 13). 

An important class of orally active ACE inhibitors, directed against the active site of ACE, is now extensively used. Captopril and enalapril are examples of the many potent ACE inhibitors that are available. These drugs differ in their structure and pharmacokinetics, but in clinical use, they are interchangeable. ACE inhibitors decrease systemic vascular resistance without increasing heart rate, and they promote natriuresis. As described in Chapters 11 and 13, they are effective in the treatment of hypertension, decrease morbidity and mortality in heart failure and left ventricular dysfunction after myocardial infarction, and delay the progression of diabetic nephropathy. 

The prospective studies have also demonstrated an association between untreated moderate-to-severe levels of OSAS and hypertension, congestive heart failure, arrhythmias, myocardial infarction, pulmonary hypertension, cor pulmonale, and stroke after adjusting for confounding factors such as obesity (29-32). Preeclampsia and averse fetal outcome have recently been described (33-36). 

Cardiovascular The most serious side effect of oral contraceptives is cardiovascular disease, including thromboembolism, thrombophlebitis, hypertension, and increased incidences of myocardial infarction and cerebral and coronary thrombosis. These adverse effects are most common among women who smoke and who are over 35 years of age, although they may affect women of any age. 

---